Dunn Jason, Lovat Laurence
University College London Hospitals NHS Foundation Trust, National Medical Laser Centre, 67 - 73 Riding House Street, London W1P 7NN, UK.
Expert Opin Pharmacother. 2008 Apr;9(5):851-8. doi: 10.1517/14656566.9.5.851.
5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the treatment of dysplasia in Barrett's oesophagus.
To investigate the use of ALA-PDT for the treatment of dysplasia and early cancer in Barrett's oesophagus.
A systematic literature review and synopsis is given.
ALA is an attractive alternative to the currently approved photosensitiser (porfimer sodium) due to its oral route of administration, shorter generalised skin photosensitivity period and lower rate of stricture formation. The studies presented demonstrate that ALA-PDT is both safe and effective for the treatment of dysplasia and early cancer in Barrett's oesophagus.
5-氨基乙酰丙酸（ALA）是内源性形成的光敏剂原卟啉IX的天然代谢前体。它通过一种称为光动力疗法（PDT）的过程局部用于治疗良性和恶性皮肤疾病。最近，有关其全身用于治疗巴雷特食管发育异常的数据正在出现。
研究ALA-PDT用于治疗巴雷特食管发育异常和早期癌症的情况。
进行了系统的文献综述和概述。
由于ALA的口服给药途径、较短的全身性皮肤光敏期和较低的狭窄形成率，它是目前已批准的光敏剂（卟吩姆钠）的一种有吸引力的替代物。所呈现的研究表明，ALA-PDT治疗巴雷特食管发育异常和早期癌症既安全又有效。
